Literature DB >> 15004159

Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells.

Ikuo Takeda1, Shoji Ine, Nigel Killeen, Lishomwa C Ndhlovu, Kazuko Murata, Susumu Satomi, Kazuo Sugamura, Naoto Ishii.   

Abstract

The OX40 (CD134) molecule is induced primarily during T cell activation and, as we show in this study, is also expressed on CD25+CD4+ regulatory T (Treg) cells. A necessary role for OX40 in the development and homeostasis of Treg cells can be inferred from the reduced numbers of the cells present in the spleens of OX40-deficient mice, and their elevated numbers in the spleens of mice that overexpress the OX40 ligand (OX40L). The homeostatic proliferation of Treg cells following transfer into lymphopenic mice was also found to be potentiated by the OX40-OX40L interaction. Suppression of T cell responses by Treg cells was significantly impaired in the absence of OX40, indicating that, in addition to its homeostatic functions, OX40 contributes to efficient Treg-mediated suppression. However, despite this, we found that CD25-CD4+ T cells became insensitive to Treg-mediated suppression when they were exposed to OX40L-expressing cells, or when they were treated with an agonistic OX40-specific mAb. OX40 signaling could also abrogate the disease-preventing activity of Treg cells in an experimental model of inflammatory bowel disease. Thus, although the data reveal important roles for OX40 signaling in Treg cell development, homeostasis, and suppressive activity, they also show that OX40 signals can oppose Treg-mediated suppression when they are delivered directly to Ag-engaged naive T cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15004159     DOI: 10.4049/jimmunol.172.6.3580

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  121 in total

1.  New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.

Authors:  Xiang Xiao; Weihua Gong; Gulcin Demirci; Wentao Liu; Silvia Spoerl; Xiufeng Chu; D Keith Bishop; Laurence A Turka; Xian C Li
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

2.  CARMA1 is necessary for optimal T cell responses in a murine model of allergic asthma.

Authors:  Ravisankar A Ramadas; Marly I Roche; James J Moon; Thomas Ludwig; Ramnik J Xavier; Benjamin D Medoff
Journal:  J Immunol       Date:  2011-11-09       Impact factor: 5.422

3.  Regeneration of dendritic cells in aged mice.

Authors:  Serani L H van Dommelen; Alexandra Rizzitelli; Ann Chidgey; Richard Boyd; Ken Shortman; Li Wu
Journal:  Cell Mol Immunol       Date:  2010-02-01       Impact factor: 11.530

Review 4.  Signaling through OX40 enhances antitumor immunity.

Authors:  Shawn M Jensen; Levi D Maston; Michael J Gough; Carl E Ruby; William L Redmond; Marka Crittenden; Yuhuan Li; Sachin Puri; Christian H Poehlein; Nick Morris; Magdalena Kovacsovics-Bankowski; Tarsem Moudgil; Chris Twitty; Edwin B Walker; Hong-Ming Hu; Walter J Urba; Andrew D Weinberg; Brendan Curti; Bernard A Fox
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

5.  Urinary cell levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and acute rejection of human renal allografts.

Authors:  Cheguevara Afaneh; Thangamani Muthukumar; Michelle Lubetzky; Ruchuang Ding; Catherine Snopkowski; Vijay K Sharma; Surya Seshan; Darshana Dadhania; Joseph E Schwartz; Manikkam Suthanthiran
Journal:  Transplantation       Date:  2010-12-27       Impact factor: 4.939

Review 6.  Advances in the development of cancer immunotherapies.

Authors:  Jianjun Gao; Chantale Bernatchez; Padmanee Sharma; Laszlo G Radvanyi; Patrick Hwu
Journal:  Trends Immunol       Date:  2012-09-30       Impact factor: 16.687

7.  Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.

Authors:  William L Redmond; Stefanie N Linch; Melissa J Kasiewicz
Journal:  Cancer Immunol Res       Date:  2013-11-11       Impact factor: 11.151

8.  OX40 costimulation turns off Foxp3+ Tregs.

Authors:  Minh Diem Vu; Xiang Xiao; Wenda Gao; Nicolas Degauque; Ming Chen; Alexander Kroemer; Nigel Killeen; Naoto Ishii; Xian Chang Li
Journal:  Blood       Date:  2007-06-15       Impact factor: 22.113

9.  Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.

Authors:  Yawara Kawano; Oksana Zavidij; Jihye Park; Michele Moschetta; Katsutoshi Kokubun; Tarek H Mouhieddine; Salomon Manier; Yuji Mishima; Naoka Murakami; Mark Bustoros; Romanos Sklavenitis Pistofidis; Mairead Reidy; Yu J Shen; Mahshid Rahmat; Pavlo Lukyanchykov; Esilida Sula Karreci; Shokichi Tsukamoto; Jiantao Shi; Satoshi Takagi; Daisy Huynh; Antonio Sacco; Yu-Tzu Tai; Marta Chesi; P Leif Bergsagel; Aldo M Roccaro; Jamil Azzi; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

10.  Effects of OX40-OX40L interaction on the nuclear factor of activated T cells c1 in ApoE-deficient mice.

Authors:  Jin-chuan Yan; Liang-jie Xu; Cui-ping Wang; Zhong-qun Wang
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.